Search Results for "benzodiazepines"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for benzodiazepines. Results 81 to 87 of 87 total matches.

Once-Monthly Subcutaneous Buprenorphine (Sublocade) for Opioid Use Disorder

   
The Medical Letter on Drugs and Therapeutics • Feb 26, 2018  (Issue 1541)
of benzodiazepines or other sedating drugs with opioids such as buprenorphine can result in additive effects ...
The FDA has approved a subcutaneous (SC) extended-release formulation of the mu-opioid receptor partial agonist and kappa-opioid receptor antagonist buprenorphine (Sublocade – Indivior) for once-monthly treatment of moderate to severe opioid use disorder. Sublocade is the first injectable buprenorphine product to be approved in the US. Buprenorphine is also available in sublingual formulations with or without the opioid antagonist naloxone, in a buccal formulation with naloxone, and as a subdermal implant (Probuphine).
Med Lett Drugs Ther. 2018 Feb 26;60(1541):35-7 |  Show IntroductionHide Introduction

Telithromycin (Ketek) for Respiratory Infections

   
The Medical Letter on Drugs and Therapeutics • Aug 16, 2004  (Issue 1189)
serum concentrations of the short-acting benzodiazepine midazolam (Versed, and others); although ...
Telithromycin (Ketek - Aventis) has been approved by the FDA for oral treatment of mild to moderate community-acquired pneumonia, acute exacerbations of chronic bronchitis and acute bacterial sinusitis in patients age 18 and older. The drug is the first in a new class of antibiotics, the ketolides, derived from the macrolide erythromycin. Telithromycin has been marketed in Europe since 2001.
Med Lett Drugs Ther. 2004 Aug 16;46(1189):66-8 |  Show IntroductionHide Introduction

Comparison Table: Some Oral/Transdermal Opioid Analgesics (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022  (Issue 1665)
, such as alcohol, general anesthetics, phenothiazines, sedative-hypnotics such as benzodiazepines or barbiturates ...
View the Comparison Table: Some Oral/Transdermal Opioid Analgesics
Med Lett Drugs Ther. 2022 Dec 12;64(1665):e199-202 |  Show IntroductionHide Introduction

Cariprazine (Vraylar) for Schizophrenia and Bipolar I Disorder

   
The Medical Letter on Drugs and Therapeutics • Apr 25, 2016  (Issue 1493)
treatment with a benzodiazepine.1 PHARMACOLOGY — Cariprazine is metabolized by CYP3A4 and, to a lesser ...
The FDA has approved cariprazine (Vraylar – Actavis), an oral, once-daily, second-generation antipsychotic, for treatment of schizophrenia and for acute treatment of manic or mixed episodes associated with bipolar I disorder.
Med Lett Drugs Ther. 2016 Apr 25;58(1493):51-3 |  Show IntroductionHide Introduction

Advice for Travelers

   
The Medical Letter on Drugs and Therapeutics • Oct 07, 2019  (Issue 1582)
of jet lag and hasten adaptation include melatonin, the benzodiazepine receptor agonist zolpidem ...
Patients who receive pretravel advice can reduce their risk for many travel-related conditions. Vaccines recommended for travelers are reviewed in a separate issue.
Med Lett Drugs Ther. 2019 Oct 7;61(1582):153-60 |  Show IntroductionHide Introduction

Drugs for Menopausal Symptoms

   
The Medical Letter on Drugs and Therapeutics • Mar 04, 2024  (Issue 1697)
is lacking.27 In one study, the benzodiazepine receptor agonist eszopiclone (Lunesta, and generics ...
The primary symptoms of menopause are genitourinary and vasomotor. The genitourinary syndrome of menopause (GSM) includes symptoms such as burning, irritation, dryness, dyspareunia, dysuria, and recurrent urinary tract infection. Vasomotor symptoms (VMS; hot flashes, night sweats) often disrupt sleep.
Med Lett Drugs Ther. 2024 Mar 4;66(1697):33-8   doi:10.58347/tml.2024.1697a |  Show IntroductionHide Introduction

Drugs and Devices for Weight Management

   
The Medical Letter on Drugs and Therapeutics • Aug 04, 2025  (Issue 1734)
abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs ■ Use within ...
Overweight is generally defined as a body mass index (BMI) between 25 and 29.9 kg/m2 in adults. A BMI ≥30 is considered obese (criteria differ slightly in Asian patients). In patients with an elevated BMI, a 5-10% reduction in weight has been associated with a reduction in the risk of developing type 2 diabetes, hypertension, and dyslipidemia. Diet, exercise, and behavior modification are the traditional methods for losing weight, but they are often inadequate; the American College of Cardiology no longer recommends that all patients try lifestyle modification alone before adding...
Med Lett Drugs Ther. 2025 Aug 4;67(1734):121-8   doi:10.58347/tml.2025.1734a |  Show IntroductionHide Introduction